Financials

News Ideas Discussions Technicals Forecast Seasonals

BGBIO fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

BGBIO does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company